INNOVACAP vs SMSPHARMA: Stock Comparison
INNOVA CAPTAB is the larger company by market capitalisation. INNOVA CAPTAB shows a lower P/E, a higher dividend yield and faster revenue growth, while SMS PHARMACEUTICALS shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INNOVACAP leads 7; SMSPHARMA leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INNOVACAP | SMSPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | INNOVACAP | SMSPHARMA |
|---|---|---|
| Live Price | ₹1,147.2 | ₹463.45 |
| Day Change | -1.73% | 11.02% |
| Volume | 44,230 | 1.04 Cr |
| 52-Week High | ₹1,200 | ₹447.8 |
| 52-Week Low | ₹622 | ₹242.25 |
| Distance from 52W High | -4.4% | 3.49% |
Valuation
| Metric | INNOVACAP | SMSPHARMA |
|---|---|---|
| Market Cap | ₹6,599 Cr | ₹4,348 Cr |
| P/E Ratio | 42.22x | 42.32x |
| P/B Ratio | 6.1x | 5.53x |
| EPS | ₹7.71 | ₹2.26 |
| Book Value | ₹188.99 | ₹83.91 |
| Dividend Yield | 0.17% | 0.09% |
Growth
| Metric | INNOVACAP | SMSPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 42.3% | -4.1% |
| EPS Growth (TTM YoY) | 28.6% | 49.2% |
| Qtr Sales Growth | 17.57% | 0% |
| Qtr Profit Growth | 37.64% | 1.07% |
Profitability & Leverage
| Metric | INNOVACAP | SMSPHARMA |
|---|---|---|
| ROE | 9.44% | 12.98% |
| ROCE | 7.89% | 9.79% |
| Net Margin | 8.65% | 11.5% |
| Operating Margin | 9.8% | 15.75% |
| Debt to Equity | 0.36x | 0.46x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | INNOVACAP | SMSPHARMA |
|---|---|---|
| Promoter Holding | 50.9% | 68.07% |
| FII Holding | 0.34%▲ 0.11 pp | 0.65%▲ 0.34 pp |
| DII Holding | 19.92%▼ 0.22 pp | 2.83%▼ 0.19 pp |
| Public Holding | 28.84%▲ 0.11 pp | 28.45%▼ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INNOVA CAPTAB and SMS PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.